News
Invizius’ ‘angry blood’ research recruits 300th patient
Invizius – a company focusing on second generation therapies autoimmune conditions – has announced that the 300th patient has been recruited to its ‘angry blood’ study.
You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.
Invizius – a company focusing on second generation therapies autoimmune conditions – has announced that the 300th patient has been recruited to its ‘angry blood’ study.